Balyasny Asset Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Balyasny Asset Management’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$42.4M	Buy	+79,011	New	+$40.5M	0.05%	416
2025 Q4	–	Sell	-82,401	Closed	-$42.1M	–	3367
2025 Q3	$37.8M	Buy	82,401 +47,901	+139%	+$17.9M	0.05%	461
2025 Q2	$10.4M	Buy	34,500 +7,285	+27%	+$2.17M	0.02%	950
2025 Q1	$9.01M	Buy	27,215 +12,987	+91%	+$4.27M	0.01%	971
2024 Q4	$4.39M	Buy	+14,228	New	+$4M	0.01%	1344
2024 Q3	–	Sell	-2,448	Closed	-$626K	–	2995
2024 Q2	$686K	Buy	+2,448	New	+$583K	﹤0.01%	1939
2023 Q4	–	Sell	-28,204	Closed	-$4.12M	–	2734
2023 Q3	$4.12M	Buy	+28,204	New	+$5.31M	0.01%	1166
2023 Q1	–	Sell	-200	Closed	-$58K	–	2956
2022 Q4	$58K	Buy	+200	New	+$19.6K	﹤0.01%	2328

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Balyasny Asset Management's MDGL Position: Q2 2026 in Review

Balyasny Asset Management opened a new position in Madrigal Pharmaceuticals (MDGL) in Q2 2026: 79,011 shares worth $42.4M. The stake represents 0.05% of the portfolio and ranks #416 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in MDGL as recently as Q3 2025.

Balyasny Asset Management first reported a position in MDGL in Q4 2022 and has held it in 8 quarters since. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

Balyasny Asset Management held 79,011 shares of Madrigal Pharmaceuticals worth $42.4M as of Q2 2026.
Madrigal Pharmaceuticals was a new Balyasny Asset Management position in Q2 2026.
Madrigal Pharmaceuticals made up 0.05% of Balyasny Asset Management's portfolio in Q2 2026, its #416 holding.
Balyasny Asset Management first reported a position in Madrigal Pharmaceuticals in Q4 2022 and has held it in 8 quarters since.
414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.